ArticleMetabolic engineering2021
Establishing recombinant production of pediocin PA-1 in Corynebacterium glutamicum.
Article in Metabolic engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Engineering of Corynebacterium glutamicum for biosynthesis of the pharmaceutically active N-acetyltyramine: establishing and optimizing de novo production.Journal of biological engineering · 2026Article
- High-copy plasmid engineering enhances recombinant protein and antimicrobial peptide production in Corynebacterium glutamicum.Microbial cell factories · 2026Article
- Current Status and Future Challenges in the Use of Bacteriocins to Modulate Ruminant Gut Microbiota.Probiotics and antimicrobial proteins · 2026Review
- The rise and future of peptide-based antimicrobials.Journal of microbiology (Seoul, Korea) · 2026Review
- Production of the Antimicrobial Roseoflavin With Genetically Engineered Corynebacterium glutamicum.Microbial biotechnology · 2025Article
- Secretory Production of Heterologous Antimicrobial Peptides inEngineering in life sciences · 2025Article
- AlleviatingAnimals : an open access journal from MDPI · 2025Article
- Antimicrobial peptide production with Corynebacterium glutamicum on lignocellulosic side streams.Biotechnology for biofuels and bioproducts · 2024Article
- Metabolic Profile of the Genome-ReducedACS synthetic biology · 2024Article
- Antimicrobial Compounds in Wine.Probiotics and antimicrobial proteins · 2024Review
- The Progress of the Biotechnological Production of Class IIa Bacteriocins in Various Cell Factories and Its Future Challenges.International journal of molecular sciences · 2024Review
- Bacteriocins: potentials and prospects in health and agrifood systems.Archives of microbiology · 2024Review
- Protective Cultures in Food Products: From Science to Market.Foods (Basel, Switzerland) · 2023Review
- High-efficiency production of the antimicrobial peptide pediocin PA-1 in metabolically engineered Corynebacterium glutamicum using a microaerobic process at acidic pH and elevated levels of bivalent calcium ions.Microbial cell factories · 2023Article
- Optimized recombinant production of the bacteriocin garvicin Q byFrontiers in microbiology · 2023Article
- Improved fluorescent Listeria spp. biosensors for analysis of antimicrobials by flow cytometry.MicrobiologyOpen · 2022Article
- Genome-assisted Identification, Purification, and Characterization of Bacteriocins.Bio-protocol · 2022Article
- Heterologous expression of pediocin/papA in Bacillus subtilis.Microbial cell factories · 2022Article
- Microbial community functioning during plant litter decomposition.Scientific reports · 2022Article
- Recombinant production of the lantibiotic nisin using Corynebacterium glutamicum in a two-step process.Microbial cell factories · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriocins are antimicrobial peptides produced by bacteria to inhibit competitors in their natural environments. Some of these peptides have emerged as commercial food preservatives and, due to the rapid increase in antibiotic resistant bacteria, are also discussed as interesting alternatives to antibiotics for therapeutic purposes. Currently, commercial bacteriocins are produced exclusively with natural producer organisms on complex substrates and are sold as semi-purified preparations or crude fermentates. To allow clinical application, efficacy of production and purity of the product need to be improved. This can be achieved by shifting production to recombinant microorganisms. Here, we identify Corynebacterium glutamicum as a suitable production host for the bacteriocin pediocin PA-1. C. glutamicum CR099 shows resistance to high concentrations of pediocin PA-1 and the bacteriocin was not inactivated when spiked into growing cultures of this bacterium. Recombinant C. glutamicum expressing a synthetic pedACD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.